Business context and reporting period
The Estée Lauder Companies Inc. manufactures and sells prestige beauty products across skin care, makeup, fragrance and hair care in approximately 150 countries and territories. This Form 10-Q covers the quarter and nine months ended March 31, 2023 (fiscal 2023 third quarter). The request metadata says “2022 Q3,” but the filing itself is for 2023 Q3.
Key financial metrics
| Metric | Three months ended March 31, 2023 | Nine months ended March 31, 2023 |
|---|---|---|
| Net sales | $3.751 billion, down 12% reported and 9% in constant currency | $12.301 billion, down 13% reported and 9% in constant currency |
| Gross profit / margin | $2.592 billion / 69.1%, versus 76.6% | $8.900 billion / 72.4%, versus 76.9% |
| Operating income / margin | $297 million / 7.9%, versus $738 million / 17.4% | $1.514 billion / 12.3%, versus $3.091 billion / 21.8% |
| Net earnings attributable to Estée Lauder | $156 million; diluted EPS $0.43, versus $558 million and $1.53 | $1.039 billion; diluted EPS $2.88, versus $2.338 billion and $6.39 |
| Operating cash flow | $1.017 billion for nine months, versus $1.969 billion | |
| Cash and cash equivalents | $5.531 billion at March 31, 2023, versus $3.957 billion at June 30, 2022 | |
| Total debt | $7.371 billion at March 31, 2023, including $2.243 billion current debt; debt was 56% of total capitalization, versus 49% at June 30, 2022 |
Nine-month investing cash outflow was $527 million, including $652 million of capital expenditures. Financing cash inflow was $1.090 billion, including $2.228 billion of net current-debt proceeds, $687 million of dividends paid and $258 million of treasury-stock purchases. The company reported $11.247 billion of current assets and $7.700 billion of current liabilities.
Material changes versus the prior comparable periods
- Sales declines were led by skin care and Asia travel retail. For the quarter, skin care sales fell 20%; makeup fell 2%; fragrance rose 1%; and hair care rose 1%.
- By region, quarterly sales increased 3% in the Americas, declined 26% in Europe, the Middle East & Africa, and declined 1% in Asia/Pacific. The EMEA decrease reflected lower Asia travel-retail shipments as retailers reduced inventory.
- Gross margin contracted 750 basis points in the quarter and 450 basis points year to date. Management cited business mix, higher inventory obsolescence and manufacturing costs.
- Quarterly operating income fell 60% and nine-month operating income fell 51%. The nine-month result included $207 million of intangible-asset impairments; the prior-year comparable period included $216 million.
- The nine-month effective tax rate rose to 27.9% from 21.1%; the quarterly rate was 44.6% versus 18.5%. The company attributed the increases primarily to the geographic mix of earnings, with lower excess stock-compensation tax benefits also affecting the nine-month comparison.
Outlook, commentary, risks and unusual items
- Management described a gradual, prolonged post-COVID recovery, particularly in Asia travel retail. Retailer inventory levels, slower travel recovery, fewer replenishment orders and Korea’s transition to post-COVID regulations remained near-term pressures. The filing provides no specific numerical sales or earnings guidance in the supplied text.
- Other stated risks include foreign-exchange volatility, inflation, recession concerns, supply-chain challenges, geopolitical tensions and potential effects on consumer demand and travel. The company had substantially scaled down Russian operations and expected to continue limited product sales; Russia and Ukraine together represented approximately 1% of fiscal 2022 sales.
- The company recorded $207 million of trademark impairments year to date: $100 million for Dr.Jart+, $86 million for Too Faced and $21 million for Smashbox. Management said the related goodwill remained recoverable, but noted further impairment could result if forecasts, product launches, expansion plans or efficiency efforts underperform.
- The Post-COVID Business Acceleration Program had cumulative charges of $376 million through March 31, 2023. Estimated total charges were $450 million to $480 million before tax; the program anticipated a net reduction of 2,500–3,000 positions and closure of approximately 10%–15% of freestanding stores globally.
- On April 28, 2023, after quarter-end, the company completed its TOM FORD brand acquisition for approximately $2.25 billion. Funding included cash, commercial paper and approximately $250 million received from continuing licensee Marcolin; a further $300 million, accruing interest at 5%, is due to sellers beginning in July 2025. The acquisition eliminates future TOM FORD Beauty license royalties.
- Commercial paper outstanding was $2.250 billion at March 31 and $3.410 billion at April 26, 2023. A $2.0 billion revolving facility was undrawn and available at March 31. Management stated that cash, operating cash flow, credit lines and market access should support planned needs.
- Management believed current legal proceedings would not have a material adverse effect; reasonably possible losses beyond accrued amounts were described as not material. The company reported effective disclosure controls as of March 31, 2023.
Important facts for investors to verify
- Whether Asia travel-retail inventory normalizes and replenishment orders recover, especially in Hainan and Korea.
- Whether gross-margin pressures from mix, obsolescence and manufacturing costs ease, and whether profitability recovers alongside sales.
- Whether the assumptions supporting Dr.Jart+ and Too Faced valuations remain achievable and whether further impairment charges arise.
- How the TOM FORD acquisition, increased commercial-paper borrowing and later seller payments affect debt, interest expense and cash generation.
- Whether subsequent company guidance quantifies the timing and pace of recovery, including effects from foreign exchange, inflation and consumer demand.